His primary areas of investigation include Internal medicine, Cardiology, Myocardial infarction, Surgery and Stroke. His study in Atrial fibrillation, Hazard ratio, Proportional hazards model, Randomized controlled trial and Coronary artery disease falls under the purview of Internal medicine. The study incorporates disciplines such as Survival rate and Angioplasty in addition to Hazard ratio.
His Surgery study combines topics in areas such as Logistic regression, Heart disease and Risk factor. His study in Stroke is interdisciplinary in nature, drawing from both Apixaban, Anesthesia, Aspirin and Warfarin. His work in Heart failure addresses subjects such as Candesartan, which are connected to disciplines such as Placebo.
Christopher B. Granger mainly investigates Internal medicine, Cardiology, Myocardial infarction, Atrial fibrillation and Stroke. His study looks at the relationship between Internal medicine and fields such as Surgery, as well as how they intersect with chemical problems. Christopher B. Granger combines topics linked to Hazard ratio with his work on Cardiology.
His work in Myocardial infarction addresses issues such as Emergency medicine, which are connected to fields such as Medical emergency. His research in Atrial fibrillation intersects with topics in Aspirin and Intensive care medicine. The various areas that Christopher B. Granger examines in his Stroke study include Anesthesia and Proportional hazards model.
The scientist’s investigation covers issues in Internal medicine, Cardiology, Atrial fibrillation, In patient and Stroke. All of his Internal medicine and Myocardial infarction, Heart failure, Percutaneous coronary intervention, Randomized controlled trial and Aspirin investigations are sub-components of the entire Internal medicine study. His Myocardial infarction research is multidisciplinary, incorporating perspectives in Coronary artery disease and Risk factor.
He focuses mostly in the field of Percutaneous coronary intervention, narrowing it down to matters related to Acute coronary syndrome and, in some cases, Conventional PCI. The concepts of his Cardiology study are interwoven with issues in Biomarker and MEDLINE. His Stroke study incorporates themes from Proportional hazards model and Hazard ratio.
Christopher B. Granger focuses on Internal medicine, Cardiology, Atrial fibrillation, Percutaneous coronary intervention and Myocardial infarction. Internal medicine is a component of his Heart failure, Acute coronary syndrome, Randomized controlled trial, Vitamin K antagonist and Hazard ratio studies. Christopher B. Granger interconnects Candesartan, Coronary stenting, Cause of death and Kidney disease in the investigation of issues within Cardiology.
His studies deal with areas such as Stroke and Aspirin as well as Atrial fibrillation. His Percutaneous coronary intervention research focuses on subjects like Antithrombotic, which are linked to Regimen. As part of one scientific family, Christopher B. Granger deals mainly with the area of Myocardial infarction, narrowing it down to issues related to the Risk factor, and often Cardiac magnetic resonance imaging, Dyslipidemia and Clinical endpoint.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger;John H. Alexander;Renato D. Lopes;Elaine M. Hylek.
The New England Journal of Medicine (2011)
Predictors of hospital mortality in the global registry of acute coronary events.
Christopher B. Granger;Robert J. Goldberg;Omar Dabbous;Karen S. Pieper.
JAMA Internal Medicine (2003)
A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry
Kim A Eagle;Michael J Lim;Omar H Dabbous;Karen S Pieper.
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
M Nikpay;A Goel;Won H-H.;L M Hall.
Nature Genetics (2015)
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Jack Hirsh;Theodore E. Warkentin;Stephen G. Shaughnessy;Sonia S. Anand.
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)
Keith A A Fox;Omar H Dabbous;Robert J Goldberg;Karen S Pieper.
CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL
J J Mcmurray;J Ostergren;K Swedberg;C B Granger.
The Lancet (2003)
Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia
Ohman Em;Armstrong Pw;Christenson Rh;Granger Cb.
The New England Journal of Medicine (1996)
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Salim Yusuf;Shamir R. Mehta;Susan Chrolavicius;Rizwan Afzal.
The New England Journal of Medicine (2006)
CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION INTOLERANT TO ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ALTERNATIVE TRIAL
C B Granger;J J Mcmurray;S Yusuf;P Held.
The Lancet (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: